Avenue Therapeutics (ATXI) Q4 2024 earnings summary

Executive summary

• Avenue Therapeutics focuses on developing therapies for neurologic diseases, with lead candidates AJ201 (SBMA), IV tramadol (post-operative pain), and BAER-101 (epilepsy/panic disorders).

• Net loss for 2024 was $11.7 million, up from $10.5 million in 2023; accumulated deficit reached $102.6 million.

• The company faces a dispute with AnnJi over the AJ201 license, which may impact clinical development and business plans.

• In March 2025, Avenue was delisted from Nasdaq and now trades on the OTC Pink Open Market.

Financial highlights

• Research and development expenses were $6.6 million in 2024, up from $6.1 million in 2023.

• No research and development license acquisition expenses in 2024, compared to $4.2 million in 2023.

• General and administrative expenses increased to $4.6 million in 2024 from $4.2 million in 2023.

• Cash and cash equivalents at year-end 2024 were $2.6 million, up from $1.8 million at year-end 2023.

• Net cash used in operating activities was $9.0 million in 2024; net cash provided by financing activities was $9.8 million.

Outlook and guidance

• The company expects to continue incurring operating losses and will require substantial additional funding to advance its pipeline.

• No plans to initiate the next Phase 3 IV tramadol study unless additional financing is secured.

• Ongoing legal dispute with AnnJi over AJ201 may delay or impact future development and commercialization.